Literature DB >> 8384653

Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model.

E Brouwer1, M G Huitema, P A Klok, H de Weerd, J W Tervaert, J J Weening, C G Kallenberg.   

Abstract

To develop an animal model for antimyeloperoxidase (MPO)-associated necrotizing crescentic glomerulonephritis (NCGN), we immunized Brown Norway rats with MPO and localized a neutrophil lysosomal enzyme extract, primarily consisting of MPO and elastinolytic enzymes, plus H2O2, the substrate of MPO, to the glomerular basement membrane (GBM). Upon immunization rats developed antibodies and positive skin tests to MPO. After unilateral perfusion of the left kidney with the lysosomal enzyme extract and H2O2, MPO and immunoglobulin (Ig)G localized transiently along the GMB. At the time of maximal inflammation, at 4 and 10 d after perfusion, MPO, IgG, and C3 could not be detected anymore. MPO-immunized rats perfused with the lysosomal enzyme extract and H2O2, in contrast to control-immunized and/or control-perfused rats, developed a proliferative GN characterized by intra- and extracapillary cell proliferation, ruptured Bowman's capsule, periglomerular granulomatous inflammation, and formation of giant cells. Monocytes, polymorphonuclear leukocytes (PMN), and to a far lesser extent T cells were found in the glomeruli. Interstitial infiltrates consisted of monocytes, PMN, and T cells. Granulomatous vasculitis of small vessels was found at 10 d after perfusion. The proliferative NCGN in this rat model closely resembles human anti-MPO-associated pauci-immune NCGN, and enables the study of the pathophysiology of anti-MPO-associated NCGN.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384653      PMCID: PMC2190976          DOI: 10.1084/jem.177.4.905

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  Fatal immune complex glomerulonephritis without deposits.

Authors:  F G Germuth; A J Valdes; J J Taylor; O Wise; E Rodriguez
Journal:  Johns Hopkins Med J       Date:  1975-05

2.  Wegener's granulomatosis: pathology and review of the literature.

Authors:  G C GODMAN; J CHURG
Journal:  AMA Arch Pathol       Date:  1954-12

3.  Immunocytochemical localization of myeloperoxidase, lactoferrin, lysozyme and neutral proteases in human monocytes and neutrophilic granulocytes.

Authors:  K B Pryzwansky; L E Martin; J K Spitznagel
Journal:  J Reticuloendothel Soc       Date:  1978-09

Review 4.  Idiopathic rapidly progressive glomerulonephritis.

Authors:  W G Couser
Journal:  Am J Nephrol       Date:  1982       Impact factor: 3.754

5.  Relapses in Wegener's granulomatosis: the role of infection.

Authors:  A J Pinching; A J Rees; B A Pussell; C M Lockwood; R S Mitchison; D K Peters
Journal:  Br Med J       Date:  1980-09-27

Review 6.  Oxygen metabolism and the toxic properties of phagocytes.

Authors:  S J Klebanoff
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

7.  Purification of human myeloperoxidase by Concanavalin A-Sepharose affinity chromatography.

Authors:  D P Merrill
Journal:  Prep Biochem       Date:  1980

8.  In situ formation of subepithelial glomerular immune complexes in passive serum sickness.

Authors:  G Fleuren; J Grond; P J Hoedemaeker
Journal:  Kidney Int       Date:  1980-05       Impact factor: 10.612

9.  Crescentic glomerulonephritis without immune deposits: clinicopathologic features.

Authors:  M M Stilmant; W K Bolton; B C Sturgill; G W Schmitt; W G Couser
Journal:  Kidney Int       Date:  1979-02       Impact factor: 10.612

10.  Renal biopsy pathology in Wegener's granulomatosis.

Authors:  R G Horn; A S Fauci; A S Rosenthal; S M Wolff
Journal:  Am J Pathol       Date:  1974-03       Impact factor: 4.307

View more
  49 in total

1.  Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis.

Authors:  R H Brons; M C de Jong; N K de Boer; C A Stegeman; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

Review 2.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

3.  Antineutrophil cytoplasmic antibody and vasculitis: much more than a disease marker.

Authors:  Vivette D'Agati
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

4.  Inhibition of human lymphocyte function by organic solvents.

Authors:  A S Shoker; M A Murabit; F F Georges; L F Qualtiere; H G Deneer; K Prasad
Journal:  Mol Cell Biochem       Date:  1997-06       Impact factor: 3.396

Review 5.  Role of T cells and dendritic cells in glomerular immunopathology.

Authors:  Christian Kurts; Felix Heymann; Veronika Lukacs-Kornek; Peter Boor; Jürgen Floege
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

6.  Animal models of vasculitides.

Authors:  Uriel Katz; Boris Gilburd; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

7.  Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat.

Authors:  P Heeringa; E Brouwer; P A Klok; M G Huitema; J van den Born; J J Weening; C G Kallenberg
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 8.  ANCA--pathophysiology revisited.

Authors:  C G Kallenberg; E Brouwer; A H Mulder; C A Stegeman; J J Weening; J W Tervaert
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

9.  Binding of proteinase 3 and myeloperoxidase to endothelial cells: ANCA-mediated endothelial damage through ADCC?

Authors:  B E Ballieux; K T Zondervan; P Kievit; E C Hagen; L A van Es; F J van der Woude; M R Daha
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

10.  Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis.

Authors:  V C Primo; S Marusic; C C Franklin; W H Goldmann; C G Achaval; R N Smith; M A Arnaout; B Nikolic
Journal:  Clin Exp Immunol       Date:  2009-12-14       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.